Cancer risk in severe alpha-1 antitrypsin deficiency: the importance of early identification
Eur Respir J
.
2022 Nov 3;60(5):2200846.
doi: 10.1183/13993003.00846-2022.
Print 2022 Nov.
Authors
Adriana-Maria Hiller
1
,
Magnus Ekström
2
,
Eeva Piitulainen
3
,
Anne Lindberg
4
,
Eva Rönmark
5
,
Hanan Tanash
3
Affiliations
1
Department of Respiratory Medicine and Allergology, Lund University, Skåne University Hospital, Malmö, Sweden adriana-maria.hiller@med.lu.se.
2
Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Respiratory Medicine and Allergology, Lund, Sweden.
3
Department of Respiratory Medicine and Allergology, Lund University, Skåne University Hospital, Malmö, Sweden.
4
Department of Public Health and Clinical Medicine, Section of Medicine, the OLIN unit, Umeå University, Umeå, Sweden.
5
Department of Public Health and Clinical Medicine, Section of Sustainable Health, the OLIN unit, Umeå University, Umeå, Sweden.
PMID:
35595322
DOI:
10.1183/13993003.00846-2022
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Neoplasms*
alpha 1-Antitrypsin / genetics
alpha 1-Antitrypsin Deficiency* / complications
alpha 1-Antitrypsin Deficiency* / diagnosis
Substances
alpha 1-Antitrypsin